['acromegaly']
['octreotide capsules', 'matching placebo']

        Inclusion Criteria:

          -  Documented evidence of active acromegaly

          -  Treatment with Somatostatin analogs injections (octreotide or lanreotide) for at least
             6 months with a stable dose for at least the last three months of therapy

          -  Biochemically controlled

        Exclusion Criteria:

          -  Patients taking injections of long-acting Somatostatin Receptor Ligands (SRLs) not as
             indicated in the label

          -  Pituitary surgery within six months

          -  Conventional or stereotactic pituitary radiotherapy any time in the past

          -  Patients who previously participated in CH-ACM-01 or OOC-ACM-302

          -  Any clinically significant uncontrolled concomitant disease

          -  Symptomatic cholelithiasis

          -  Pegvisomant, within 24 weeks

          -  Dopamine agonists, within 12 weeks

          -  Pasireotide, within 24 weeks
      